What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact?

This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations.

In this episode, Joon Chang covers:

• (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites

• (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes

• (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations

• (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking

• (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships

If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Joon Chang

LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction at the DCAT Conference

00:33 Overview of Lotte Biologics and market positioning

01:20 Capabilities in biologics manufacturing and conjugation

02:01 Challenges of entering the CDMO market as a new player

03:05 Importance of talent and retained expertise from legacy sites

03:52 Building relationships with Pharma and biotech clients

04:24 Dual hub model across the US and South Korea

05:01 Manufacturing scale advantages and commercial readiness

06:19 Speed, cost efficiency, and internal tech transfer benefits

07:00 Career journey from Pharma to CDMO leadership

08:04 Understanding client mindset from both Pharma and CDMO perspectives

08:54 Project management experience and client relationship ownership

09:43 Leadership philosophy and full lifecycle thinking

10:10 Building an ideal organisational culture

10:40 Patient-centric approach and ultra-rare disease considerations

11:43 Connecting operations to patient impact

12:34 Applying culture to commercial and sales teams

13:21 Business development mission and value creation

13:40 Leadership approach and empowering teams

15:00 Vision for disrupting the CDMO industry

16:21 Growth, partnerships, and expanding patient reach

17:01 Personal motivation and purpose behind the work

18:00 Team culture and collaboration

#MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing

Hosted on Acast. See acast.com/privacy for more information.

From hands-on pharmacology research to leading strategic projects in advanced manufacturing, this episode explores what it really takes to evolve, adapt, and lead across decades of change in life sciences.

This week on Making It In Manufacturing, Harry Sloan sat down with Alison Clayton, Strategic Projects Director at Symbiosis, with over 40 years of experience spanning pharmacology research, pre-clinical and clinical development, and pharmaceutical manufacturing.

In this episode, Alison Clayton covers:

(00:00) Transitioning from academia into industry and navigating major company acquisitions early in a career

(01:40) Moving beyond the lab into strategic, customer-facing roles and discovering a passion for leadership

(03:35) Adapting to constant organisational change while maintaining a patient-first mindset

(07:26) The risks of scaling too quickly in CDMOs and the importance of realistic capacity and strong partnerships

(10:02) Maintaining quality and regulatory standards while growing in a highly competitive pharmaceutical landscape

This conversation offers a grounded perspective on long-term career development, leadership in complex environments, and the evolving demands of pharmaceutical manufacturing. If you are building a career in life sciences or scaling within a CDMO environment, this episode provides practical insights worth applying.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Alison Clayton

LinkedIn: https://www.linkedin.com/in/alison-clayton-78816711/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction to the episode

00:14 Alison Clayton introduction and career reflection

00:53 Transition from academia to industry

01:15 Experience at Syntex Pharmaceuticals, Roche, and Quintiles

01:40 Moving into strategic and customer-facing roles

02:24 Leadership style shaped by scientific background

02:50 End-to-end experience across drug development

03:13 Navigating challenges and career-defining moments

03:35 Adapting through multiple company transitions

04:24 Balancing commercial goals with patient outcomes

04:56 Experiences in a male-dominated industry

05:51 Advice for women in life sciences leadership

06:09 Career development without a fixed plan

07:00 Balancing career and family life

07:26 Scaling challenges in CDMOs

08:30 Risks of overpromising and underdelivering

09:28 Importance of supply chain and transparency

10:02 Maintaining quality and regulatory compliance

10:27 Overview of Symbiosis

10:57 Market demand for sterile manufacturing

11:20 Scottish identity and company culture

11:39 Differentiation in the CDMO market

12:31 Importance of flexibility and partnerships

13:21 Building long-term client relationships

13:41 Future outlook for Symbiosis

14:05 Evolution of biologics and impact on patients

14:32 Career reflection and delivering medicines to patients

15:17 What excites Alison about the future

#MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #LifeSciences #CDMO #Biologics #DrugDevelopment

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

The CDMO model is evolving fast, but what actually separates the leaders from the rest in today’s market?

This week on Making It In Manufacturing, Harry Sloan sat down with Thierry Van Nieuwenhove, CEO of Quotient Sciences, with 25+ years of experience spanning business development, engineering, global manufacturing leadership, and executive roles.

In this episode, Thierry covers:

• The evolution of the CDMO landscape over 25 years, from API-focused events to a global, multi-disciplinary pharma ecosystem

• How Quotient Sciences built a unique translational pharmaceutics platform to combine clinical studies with drug manufacturing, accelerating development timelines by up to 12 months

• A career journey from chemical engineering into global business development and leadership, including building manufacturing capabilities in India and working across Europe and the US

• Why speed, efficiency, and proof of concept are critical in today’s funding-constrained biotech environment

• The growing impact of AI, global innovation shifts including China, and how CDMOs must adapt to remain competitive and support emerging biotech pipelines

If you are looking to understand where the CDMO space is heading, and what it takes to lead in a rapidly evolving pharmaceutical market, this episode offers a clear and practical perspective. Be sure to watch the full conversation.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Thierry Van Nieuwenhove

CEO at Quotient Sciences

LinkedIn: https://www.linkedin.com/in/thierryvan/

Harry Sloan

BD CDMO Lead

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction to Making It In Manufacturing at DCAT

00:20 Meet Thierry Van Nieuwenhove, CEO of Quotient Sciences

01:40 Overview of Quotient Sciences and translational pharmaceutics

03:10 Competitive advantage in the CDMO market

04:23 Career journey from engineering to CEO

07:00 Leadership development across global roles

08:18 Operating across international markets and cultures

09:17 Translating early-stage assets into clinical success

12:00 Industry challenges including funding constraints

14:25 AI, partnerships, and innovation in formulation

16:01 Data science and accelerating development timelines

17:32 Global trends including China’s role in innovation

19:56 Strategic adaptation to industry shifts

21:34 Demand for integrated CDMO models

22:55 Customer expectations: speed, excellence, and innovation

25:28 The importance of trust and long-term partnerships

#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #Biotech #DrugDevelopment #LifeSciences

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it really take to move from science into CEO leadership while delivering real impact for patients?

This week on Making It In Manufacturing, Harry Sloan sat down with Dr Adriana Kiedzierska-Mencfeld, CEO of Rezon Bio, with 20 years of experience spanning biotech, biologics manufacturing, and leadership across industry and scientific roles.

In this episode, Dr Adriana Kiedzierska-Mencfeld covers:

- Transitioning from academia to industry and the drive to turn science into real patient value

- Key leadership moments including entering new technology areas and managing high-pressure decision making

- Leading through COVID, maintaining operations, and ensuring both product delivery and team safety

- Transforming into a CDMO model and leading organisational change with clarity and purpose

- Competing in a crowded CDMO market through cost discipline, quality standards, and operational efficiency

If you are working in biotech, manufacturing, or scaling scientific innovation into real-world impact, this conversation offers a clear and grounded perspective on leadership, decision making, and building high-performing teams under pressure.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Dr Adriana Kiedzierska-Mencfeld

LinkedIn: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:33 Moving beyond science into leadership

02:06 Career-defining moments and leadership growth

04:56 Leading through COVID and regulatory pressure

06:01 FDA inspection and managing high-stakes environments

07:13 Transition to CDMO and company transformation

09:20 Launch of Resins Bio and stepping into CEO role

11:39 Building trust and delivering for clients

12:29 Cost competitiveness and market positioning

14:20 Speed, quality, and CDMO differentiation

15:22 Market trends and opportunities in biologics

17:33 CDMO positioning and capabilities

18:09 Balancing existing clients and new business

20:08 Personal career journey and challenges

21:44 Advice for women in biotech leadership

22:46 Future of biologics manufacturing

24:33 Motivation and leadership purpose

#MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #LifeSciences #ManufacturingLeadership

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it take to scale pharmaceutical packaging operations globally while maintaining flexibility, quality, and speed to market? In this episode, we explore how strategic packaging partnerships directly impact patient access and commercial success.

This week on Making It In Manufacturing, Harry Sloan sat down with Peter Belden, CCO of Tjoapack, with over 25 years of experience spanning outsourced pharmaceutical services across small, mid-sized, and large organisations, primarily within packaging and global supply chain operations.

In this episode, Peter Belden covers:

00:00 How pharmaceutical packaging plays a critical role beyond the final step, directly influencing timelines and global market access

01:25 The growing need for late-stage customisation and flexible packaging to meet changing patient demand across multiple markets

02:21 Why successful CDMO partnerships start with deep client understanding, including patient population, dosing, and supply chain needs

03:43 Balancing speed to market with quality through strong planning, collaboration, and supply chain alignment

04:43 Strategic expansion in the US, including facility growth and new packaging lines to support long-term demand

This conversation offers a practical look at how packaging strategy, operational discipline, and global experience come together to support pharmaceutical innovation at scale. If you are involved in manufacturing, supply chain, or CDMO partnerships, this episode provides valuable perspective grounded in real industry execution.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Peter Belden

LinkedIn: https://www.linkedin.com/in/petersbelden/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:15 Overview of the company and CDMO positioning

01:04 Evolution of pharmaceutical packaging and flexibility

01:48 Late-stage customisation and supply chain adaptability

02:21 Building strong client partnerships in packaging

02:56 Scoping projects and delivering tailored solutions

03:21 Industry change and demand for speed to market

03:43 Balancing quality with responsiveness

04:20 Supply chain collaboration and planning cadence

04:34 US expansion and growth strategy

05:06 Facility expansion and new packaging lines

05:31 Managing growth and operational challenges

06:07 Long-term vision and scaling capabilities

06:50 Career journey into leadership

07:31 International experience and UK market integration

08:39 Adapting to global markets and client needs

09:03 Delivering across 40+ countries

10:05 Motivation and impact on patient access

10:22 Closing remarks

#MakingItInManufacturing #ARTOTalent #PharmaManufacturing #CDMO #SupplyChain #Biopharma

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it really take to build a world-class pharmaceutical manufacturing business from the ground up while navigating risk, regulation, and rapid innovation?

This week on Making It In Manufacturing, Harry Sloan sat down with David Stevens, CEO of Kindeva, with over 20 years of experience spanning CDMO leadership, startup scale-ups, and pharmaceutical manufacturing across both Europe and the United States, including leadership roles at Kindeva and prior ventures acquired within the pharma ecosystem.

In this episode, David Stevens covers:

(00:01:02) Transitioning from startup CEO to leading Kindeva, and the strategic vision behind building advanced sterile fill-finish capabilities

(00:02:50) Scaling a biologics CDMO from zero to 250 employees during COVID, including lessons from building facilities and teams from scratch

(00:05:41) The future of inhalation technologies, including the shift to low-carbon propellants and the impact on sustainability and patient choice

(00:07:44) Designing next-generation sterile manufacturing facilities with Annex 1 compliance, advanced robotics, and contamination risk reduction

(00:09:57) Why trust, transparency, and operational discipline are critical in a competitive CDMO landscape, especially when managing capacity and client expectations

If you are working in pharmaceutical manufacturing, CDMO strategy, or scaling complex life sciences operations, this conversation offers a grounded perspective on leadership, growth, and building for long-term impact.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

David Stevens

LinkedIn: https://www.linkedin.com/in/davecstevens/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:14 Guest introduction and CEO journey

01:02 Career background and move into @Kindeva

02:50 Building and scaling a biologics CDMO

05:41 Vision for inhalation technology and sustainability

07:44 Future of sterile manufacturing and facility design

09:57 Trust and partnerships in CDMO relationships

12:12 Managing growth, capacity, and reputation

12:36 Long-term vision and defining success as CEO

#MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #CDMO #Biologics #LifeSciences #ManufacturingLeadership

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it really take to move from science into CEO leadership while delivering real impact for patients?

This week on Making It In Manufacturing, Harry Sloan sat down with Dr Adriana Kiedzierska-Mencfeld, CEO of Rezon Bio, with 20 years of experience spanning biotech, biologics manufacturing, and leadership across industry and scientific roles.

In this episode, Dr Adriana Kiedzierska-Mencfeld covers:

- Transitioning from academia to industry and the drive to turn science into real patient value

- Key leadership moments including entering new technology areas and managing high-pressure decision making

- Leading through COVID, maintaining operations, and ensuring both product delivery and team safety

- Transforming into a CDMO model and leading organisational change with clarity and purpose

- Competing in a crowded CDMO market through cost discipline, quality standards, and operational efficiency

If you are working in biotech, manufacturing, or scaling scientific innovation into real-world impact, this conversation offers a clear and grounded perspective on leadership, decision making, and building high-performing teams under pressure.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Dr Adriana Kiedzierska-Mencfeld

LinkedIn: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:33 Moving beyond science into leadership

02:06 Career-defining moments and leadership growth

04:56 Leading through COVID and regulatory pressure

06:01 FDA inspection and managing high-stakes environments

07:13 Transition to CDMO and company transformation

09:20 Launch of Resins Bio and stepping into CEO role

11:39 Building trust and delivering for clients

12:29 Cost competitiveness and market positioning

14:20 Speed, quality, and CDMO differentiation

15:22 Market trends and opportunities in biologics

17:33 CDMO positioning and capabilities

18:09 Balancing existing clients and new business

20:08 Personal career journey and challenges

21:44 Advice for women in biotech leadership

22:46 Future of biologics manufacturing

24:33 Motivation and leadership purpose

#MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #LifeSciences #ManufacturingLeadership

Hosted on Acast. See acast.com/privacy for more information.

What if you could access GMP manufacturing without giving up control, ownership, or flexibility? In this episode, a new model challenges how biotech companies think about scaling.

This week on Making It In Manufacturing, Harry Sloan sat down with Sarah Stevens, CEO of Chrysalis, with over 20 years of experience spanning CDMO services, technical operations, and leadership roles across biopharma manufacturing.

In this episode, Sarah Stevens covers:

(00:00) How Chrysalis is redefining the CDMO model with a hybrid approach that allows companies to retain control of IP, timelines, and manufacturing processes

(02:20) Why today’s biotech environment demands more flexible, cost-conscious manufacturing strategies and how companies can better manage capital allocation

(04:25) Where biotech companies get manufacturing strategy wrong when balancing speed versus long-term scalability in GMP processes

(08:57) A 20-year career journey from academic research into executive leadership and what drives success in CDMO environments

(13:21) How Chrysalis evolved its model into a scalable and mobile platform, enabling customers to transition seamlessly into their own facilities

If you are navigating manufacturing strategy, scaling operations, or evaluating CDMO partnerships, this episode offers a clear perspective on how to approach flexibility, control, and long-term success in biopharma.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Sarah Stevens

LinkedIn: https://www.linkedin.com/in/sarah-stevens-1135964

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

#MakingItInManufacturing #ARTOTalent #Biopharma #CDMO #GMP #BiotechManufacturing #LifeSciences

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren't following, please check!

How do you bring a $400M biotech facility online… without getting automation wrong?

This week, in another episode of Making It in Manufacturing, we feature Daniel Shearer, Head of Automation at FUJIFILM, with over 15+ years of experience spanning automation engineering, capital projects, and large-scale biotech manufacturing environments.

In this episode, Dan covers:

- The $400M multi-modal manufacturing asset at Fujifilm’s Billingham site and what it takes to bring it online

- How automation has evolved over the past decade and why data integration is now critical

- The importance of standardisation, and how it can reduce cost, validation time, and complexity

- Integration challenges across systems like MES, LIMS, and quality platforms

- The most common pitfalls in automation projects, and how to avoid them

Whether you're building a new facility or scaling existing operations, this episode is packed with practical insights from someone working at the forefront of modern biomanufacturing.

👉 Be sure to check out the full episode and learn how to get automation right from day one.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent/?viewAsMember=true

Spotify: https://open.spotify.com/show/0kEcRZO...

Instagram: https://www.instagram.com/arto.talent...

TikTok: https://www.tiktok.com/@artotalent?_t...

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@artotalent

Daniel Shearer

Head of Automation at FUJIFILM Biotechnologies

LinkedIn: https://www.linkedin.com/in/daniel-shearer-80574b36/

Thomas McMann

Director - Contracts Division

LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/

Timestamps:

00:24 $400M Multi-Modal Asset

01:38 Automation Challenges

06:59 Standardisation

11:18 Integration + Common Pitfalls

Hosted on Acast. See acast.com/privacy for more information.

Building a CDMO capable of taking therapies from early discovery to commercial supply requires more than scale. It requires scientific depth, operational discipline and a culture that embraces problems rather than avoids them.

This week on Making It In Manufacturing, Harry Sloan sat down with Philippe Clavel, CEO of Curapath, bringing decades of experience across pharmaceutical manufacturing, leadership and CDMO strategy.

In this episode, Philippe Clavel covers:

• The evolution of CuraPath from a university spin-off focused on polymer science to a drug delivery CDMO serving biotech and large pharmaceutical companies (00:00)

• Why deep scientific expertise in polymer science and lipid nanoparticles is essential for solving complex drug delivery challenges and improving manufacturing processes (02:29)

• How CuraPath transitioned from early-stage discovery work to commercial manufacturing, growing from 0% commercial revenue to roughly 30% within five years (05:14)

• The operational realities of scaling into GMP manufacturing, including building robust processes, documentation and training across the organisation (10:12)

• Why successful CDMO partnerships are built on trust, technical questioning and understanding the deeper motivations behind a customer’s drug development programme (17:00)

If you’re interested in the realities of scaling a specialist CDMO, building high-trust biotech partnerships and transforming scientific innovation into manufacturable therapies, this conversation offers valuable insight from someone leading that journey firsthand.

Follow ARTO

LinkedIn: / artotalent

Spotify: https://open.spotify.com/show/0kEcRZO...

Instagram: https://www.instagram.com/arto.talent...

TikTok: https://www.tiktok.com/@artotalent?_t...

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Website: https://arto-talent.com/

Youtube: @life_sciences

Philippe Clavel

LinkedIn: / philippe-clavel-cdmo-gxapis

Harry Sloan

/ harry-sloan-605620154

Timestamps

00:00 Introduction

00:17 Overview of CuraPath and its drug delivery focus

02:29 What differentiates CuraPath as a CDMO

04:00 Balancing cost, scalability and complex modalities

05:14 Growth from discovery projects to commercial manufacturing

06:10 Expanding expertise from polymers to lipid nanoparticle technologies

07:41 Supporting customers across the full development journey

09:21 The significance of delivering a therapy reaching the market

10:12 Transitioning to GMP manufacturing and operational discipline

11:34 Challenges that come with scaling CDMO operations

13:27 Building a culture that embraces problems and deviations

15:27 Understanding customer motivations and building trust

18:24 Collaboration across supply chains within drug manufacturing

21:17 Maintaining company culture while scaling leadership

23:32 Encouraging challenge and empowerment within teams

27:13 Advice for business development professionals in CDMO

31:08 Future outlook for CuraPath and its pipeline

34:25 Personal motivation behind leading the company

39:02 Episode closing

#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDelivery #Biotech #LifeSciences

Hosted on Acast. See acast.com/privacy for more information.